Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apalutamide - Janssen Research and Development

Drug Profile

Apalutamide - Janssen Research and Development

Alternative Names: ARN-509; ERLEADA; ERLYAND; JNJ-56021927; JNJ-927

Latest Information Update: 25 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aragon Pharmaceuticals; University of California
  • Developer Case Comprehensive Cancer Center; Dana-Farber Cancer Institute; Instituto do Cancer do Estado de Sao Paulo; Janssen Research & Development; M. D. Anderson Cancer Center; Singapore General Hospital
  • Class Antiandrogens; Antineoplastics; Aza compounds; Benzamides; Pyridines; Small molecules; Spiro compounds; Sulfhydryl compounds; Thiohydantoins
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer

Most Recent Events

  • 06 Nov 2019 Janssen Research & Development plans a phase I pharmacokinetic trial (In volunteers) in USA (PO) (NCT04154774)
  • 30 Sep 2019 Efficacy data from a phase III SPARTAN trial in Prostate caner released by Janssen
  • 18 Sep 2019 Launched for Prostate cancer (Adjunctive treatment, Metastatic disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top